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Abstract 
The effect of transforming growth factor & (TGF-&) on the expression of mRNA for the parathyroid hormone receptor and 
binding of iodinated parathyroid hormone-related protein in ROS 17/2.8 osteosarcoma cells was evaluated. TGF-8, stimulated a 
2-7-fold increase in steady state mRNA levels for the parathyroid hormone receptor at a maximal dose of 5 ngfml, with 
increased levels of expression at 6 h of TGF-&-incubation, and peak levels at 8-24 h. Receptor binding studies revealed a 
significant increase in PTHrP-specific binding with TGF-& doses as low as 0.5 ng/ml and a 55% increase in numbers of 
receptors with no alteration in binding affinity with 5.0 ngfml TGF-PI. Time course studies indicated that receptor birding was 
increased at 24 h with peak levels reached at 48 h of treatment. PTH-stimulated CAMP levels were significantly increased in 
ROS 17/2.8 cells treated with TGF-fir (0.5 ng/ml) for 48 h. These data indicate that TGF-P, upregulates steady-state mRNA, 
ligand binding and PTH/PTHrP receptor signaling in rat osteosarcoma cells. The effects of TGF-@, on bone may be attributed 
in part to regulation of the PTHfPTHrP receptor at the molecular level. 
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1. introduction 
Parath~oid hormone (PTH) and paratbyroid hor- 
mone-related protein (PTI-IrP) exert their effects on 
bone by binding to the same cell membrane receptor 
on osteoblasts (Jiippner et al., 1988; Nissenson et al., 
1988). The cDNA for the PTH/PTHrP receptor has 
recently been cloned and sequenced and belongs to the 
family of G protein-coupled receptors with seven trans- 
membrane domains (Jiippner et al., 1991). PTH and 
PTHrP bind to the ~/PTHrP receptor with similar 
affinity resulting in intracellular accumulation of CAMP 
and inositol trisphosphate and increased levels of intra- 
* Corresponding author. Tel.: (313) 763-2105; Fax (313) 7474024. 
cellular calcium (Abou-Samra et al., 1992; Jiippner et 
al., 1991). Characterization of the binding affinity and 
numbers of receptors per cell on osteoblasts has been 
extensively investigated and reviewed (Pun et al., 1990; 
Orloff et al., 1989). Information regarding local and 
systemic regulation of the PTH/PTHrP receptor is not 
well known. Transfo~ing growth factor-/3 (TGF-j3) is 
a polypeptide growth factor localized in high concen- 
trations in bone (Pfeilschifter et al., 1990). It has been 
found to regulate several osteoblast phenotype charac- 
teristics including alkaline phosphatase activity, colla- 
gen synthesis, osteopontin and osteocalcin levels 
(Centrella et al., 1988). PTH opposes the effects of 
TGF-j? on mitosis, collagen production, and alkaline 
phosphatase activity in rat calvarial cells (Centrella et 
al., 1988); however, little is known regarding the ability 
of TGF-P to modulate PTH or PTHrP effects. TGF-/3, 
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has been reported to stimulate production of PTHrP 
from uterine cells, keratinocytes, and squamous cancer 
cells (Casey et al., 1992; Merryman et al., 1993; Allinson 
and Drucker, 1992; Kiriyama et al., 1993) and to accen- 
tuate the PTH-stimulated CAMP response in UMR 106 
osteoblastic cells (Gutierrez et al., 1990). These find- 
ings suggest that TGF-#3 plays a key role in the func- 
tions of PTH/~HrP in bone; however, the ability of 
TGF-@ to alter expression of mRNA for the 
PTH/PTHrP cell surface receptor on osteoblasts is not 
known. The purpose of this study was to determine if 
TGF-P, alters PTH/PTHrP receptor mRNA levels 
and subsequently receptor binding and signaling in 
ROS 17/2.8 osteosarcoma cells. 
2. Materials and methods 
2.1. Ceil culture 
ROS 17/2.8 osteosarcoma cells (Majeska et al., 
1980) were maintained in DMEM-F12 media contain- 
ing 5% fetal bovine serum in a humidified, 5% CO,, 
37°C incubator. Cell culture media and supplements 
were obtained from Gibco (Grand Island, NY). 
2.2. Nor~~e~ blot analysis 
ROS 17/2.8 cells were grown 24-48 h post-con- 
fluence prior to placement of TGF-& (recombinant 
human, R & D Systems, Minneapolis, MN) or vehicle 
control in serum-free DMEM-F12 media for desig- 
nated time periods. Total RNA was isolated from one 
75 cm* flask per treatment by the guanidinium isothio- 
cyanate method (Chomczynski and Sacchi, 1987) and 
quantitated by A,,. Total RNA (20 pg) was denatured 
and electrophore~d in sample buffer (50% for- 
mamide, 10% MOPS buffer, 18% formaldehyde, 10% 
glycerol, 0.5% bromophenol blue, 1 pg ethidium bro- 
mide) on 1.2% agarose-formaldehyde gels (60 V, 4.5 h). 
The RNA was transferred to nylon membranes (Dura- 
lon U.V., Stratagene, La Jolla, CA) via passive trans- 
fer, and crosslinked by U.V. transillumination (Strata- 
linker, Stratagene Inc.). The nylon membranes were 
pre-hybridized for 1 h at 42°C (53% formamide, 5 X 
SSC, 100 mM Tris, 10 x Denhardt’s, 0.2% SDS and 1 
mg/ml denatured salmon sperm DNA) in a hybridiza- 
tion oven. The rat PTH/PTHrP receptor cDNA probe 
(RISE)) (Abou-Samra et al., 1992) was prepared from a 
1810 bp coding region cDNA fragment subcloned into 
pcDNA I (Invitrogen, San Diego, CA) and was labeled 
with [cw32P]dCTP (NEN DuPont, Boston, MA) using a 
random primer labeling kit (Stratagene) to lo9 
dpm/pg. The probe was added to the pre-hybridiza- 
tion tube with the membrane and hybridized overnight 
at 42°C. The membranes were washed 8 times for 15 
min each wash at 50°C with decreasing concentrations 
of SSC (2 x -0.25 x ) in 0.1% SDS. The blots were 
exposed to Kodak X-OMAT film at - 70°C with inten- 
sifying screens, and developed in an automatic film 
processor. Blots were also stripped and reprobed with 
a cDNA probe for 185 rRNA (de Papp and Stewart, 
1993) as a control for even loading. 
2.3. Binding assays 
PTH/PTHrP receptor binding assays were per- 
formed as described (McCauley et al., 1992a). Briefly, 
ROS 17/2.8 cells, grown to confluence in 24-well 
plates, were pretreated with TGF-& or control vehicle 
in DMEM-F12 media containing l-2% fetal bovine 
serum for 48 h. For binding assays triplicate wells were 
incubated with 250~-350~ cpm of monoiodinated 
[‘2511PTHrP (l-36) (McCauley et al., 1992b) in addi- 
tion to varying concentrations of nonradioactive PTHrP 
(l-36) (Bachem, Torrance, CA). The cells were incu- 
bated for 2 h at 4°C with gentle shaking. The unbound 
peptides were washed off the cell monolayer twice with 
Hank’s buffered salt solution (HBSS), the cells were 
lysed with 0.5 M NaOH for 30 min, and the resultant 
suspension counted in a scintillation counter. Specific 
binding was calculated by subtracting the radioactivity 
bound in the presence of excess unlabeled PTHrP 
(l-36) (1.0 FM) from that observed in the presence of 
tracer only and expressed as a ratio of the total cpm 
added. 
2.4. Adenylate cyclase stimulation assay 
The adenylate cyclase stimulation assay and CAMP 
binding assay were performed as previously described 
(McCauley et al., 1992b). Briefly, ROS 17/2.8 cells 
were grown 24-48 h postcon~uence in 24-well plates. 
TGF-& or vehicle control was preincubated with con- 
fluent ROS cells in triplicate for 48 h with a media 
change at 24 h. The cells were rinsed and incubated 
with bPTH (l-34) (Bachem) (10 nM) or control vehicle 
for 10 min at 37°C in calcium- and magnesium-free 
HBSS containing 0.1% bovine serum albumin (BSA) 
and 1 mM isobutylmethylxanthine (IBMX). The media 
was aspirated and 250 ~1 ice-cold 5% perchloric acid 
was added to each well. The plates were incubated at 
-20°C overnight to extract the CAMP. After thawing, 
the extract was transferred to tubes, the pH was ad- 
justed to 7.5 with 4 N KOH, and the extract was 
centrifuged to remove the precipitate. The neutralized 
extract was then assayed for CAMP content using a 
CAMP binding protein assay. Parallel wells were ana- 
lyzed for cell number by trypan blue dye enumeration. 
The CAMP binding protein assay was performed as 
follows. To each tube was added assay buffer (50 mM 
Tris, 5 mM EDTA, pH 7.4) 100 ~1 standards or un- 
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knowns, E3H]cAMP (10000 cpm/tube), and CAMP 
binding protein sufficient to bind 40-60% of the ra- 
dioactivity in a final volume of 250 ~1. The tubes were 
incubated for 90 min on ice. Dextran-coated charcoal 
(0.5 mg/ml d xt e ran and 5.0 mg/ml charcoal) was 
added to each tube (600 ~0, incubated an additional 
30 min on ice, then centrifuged to remove the unbound 
from the bound ALP-binding protein-[ 3H]cAMP 
complexes. The supernatant was decanted directly into 
scintillation vials and counted in a liquid scintillation 
spectrophotometer. Samples were run in duplicate and 
the concentration of CAMP was calculated by the iog- 
logit method using Securia 1.0 (Packard Instruments, 
Indianapolis, IN). Data were expressed as pmol 
cAMP/103 cells. 
2.5. Statistical analysh 
Data for the % specific binding and adenylate cy- 
clase assays were evaluated using Instat 1.1 (Graph- 
PAD Software, San Diego, CA) and an MS/DOS 
computer. Analysis of variance followed by multiple 
comparisons using a Tukey’s mean separation test were 
used to determine statistically significant (p < 0.05) 
differences between groups. Scatchard analysis of the 
binding curve for PTHrP was performed with LIG- 
AND, a nonlinear curve fitting software program 
(Munson and Robard, 1980). Autoradiographs from 
the northern blot analysis were evaluated for relative 
Control 
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Fig. 1. Northern blot analysis of PTH/PTHrP receptor mRNA in 
ROS 17/2.8 cells. Total RNA was isolated from control and TGF- 
@,-treated (5.0 ng/ml) ROS ceils (12 h) and 10 or 20 pg of each was 
run on a 1.2% agarose-fo~aIdehyde gel. The RNA was transferred 
onto a nylon filter and hybridized to a cDNA probe for the 
PTH/PTHrP receptor (R15B). (A) Autoradiograph of northern blot 
for PTH/PTHrP receptor, (B) ethidium bromide stained gel of 
autorad~o~aph in A, (Cl autoradiograph of Northern blot for 18s 
rRNA, (D) densitometric ratio of signal intensity for PTH/PTHrP 
receptor vs. 18s rRNA. There was a 3-7-fold increase in 
PTH/PTHrP receptor mRNA with TGF-&, treatment. 
TGFf3, 
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Fig. 2. Northern blot analysis of PTH/PTHrP mRNA expression in 
ROS 17/2.8 cells treated with TGF-P, (O-10 ng/ml) for 6 h. (A) 
Autoradiograph of Northern blot for PTH/PTHrP receptor, (B) 
autoradiograph of Northern blot for 18s rRNA, (C) densitometric 
ratio of signal intensity for PTH/PTHrP receptor vs. 18s rRNA. 
There was an increase in mRNA expression up to 5.0 ng/mi, and a 
reduction in expression at 10 ng/ml. 
signal density with NIH Image Software on a Macin- 
tosh computer. 
3. Results 
3.1. Northern blot analysis 
Northern blot analysis revealed a 3-7-fold increase 
in expression of mRNA for the PTH/PTHrP receptor 
when ROS cells were treated with TGF-P, (5.0 ng/ml) 
for 12 h (Fig. 1). TGF-j3, stimulated a dose-dependent 
increase in mRNA expression up to 5.0 ng/ml, with a 
diminution of message expression at 10 ng/ml (Fig. 2). 
Time dependence studies revealed a two-fold increase 
in PTH/~HrP receptor mRNA expression after 6 h 
of TGF-& (5.0 ng/ml) treatment and up to three-fold 
increases in mRNA expression at 24 h of treatment 
(Fig. 3). When TGF-&-treated ROS 17/2.8 cells were 
incubated in the presence of ~~lohexamide there was 
TGFD, 
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Fig. 3. Northern blot analysis of PTH/PTHrP mRNA expression in 
ROS 17/2.8 cells treated for O-24 h with TGF-P, (5.0 ng/ml). (A) 
Autoradiograph of Northern blot for PTH/PTHrP receptor, (B) 
autoradiograph of Northern blot for 18s rRNA, (Cl densitometric 
ratio of signal intensity for PTH/PTHrP receptor vs. 18s rRNA. 
Expression of PTH/PTHrP mRNA was increased 2-fold at 6 h and 
peaked at 8-24 h. 
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Fig. 4. Northern blot analysis of PTH/PTHrP receptor mRNA in 
ROS 17/2.8 cells treated for 6 h with TGF-/3, (5.0 ng/ml) or control 
in the presence of cyclohexamide (CHX) (0, 2.0 or 4.0 mM). (A) 
Autoradiograph of Northern blot for PTH/PTHrP receptor, (B) 
autoradiograph of Northern blot for 18s rRNA, (C) densitometric 
ratio of signal intensity for PTH/PTHrP receptor vs. 18s rRNA. 
CHX was effective in blocking the TGF-Pi-mediated increase in 
PTH/PTHrP receptor mRNA. 
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Fig. 5. Effects of TGF-& (O-5.0 ng/ml; 48 h in media containing 1% 
FBS) on [t*‘I]PTHrP binding to ROS 17/2.8 cells. Specific binding is 
the total cpm bound with no added unlabeled PTHrP minus the cpm 
bound in the presence of excess unlabeled PTHrP (1 PM) and is 
expressed as a percent of the total cpm (2.5000) added per well. Data 
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Fig. 6. Competitive inhibition of [‘“I]PTHrP (35000 cpm/well) 
binding to ROS 17/2.8 cells pretreated (48 h in media containing 
2% FBS) with TGF-j?, (5.0 ng/ml) by unlabeled PTHrP (O-1000 
nM). There was higher specific binding of PTHrP to the TGF-Pi- 
treated cells. Data expressed as mean f SEM of triplicate wells. 
Table 1 
Scatchard analysis of PTHrP binding to ROS cells 







K, values and number of receptors/cell were calculated from data 
in Fig. 6 by Scatchard analysis. 
a loss of the TGF-/3,-upregulation of PTH/PTHrP 
receptor mRNA levels (Fig. 4). This indicates that 
TGF-/3, is dependent on protein synthesis to mediate 
its effects on the PTH/PTHrP receptor. 
3.2. Binding assays 
TGF-/3, stimulated an increase in specific binding of 
iodinated PTHrP to ROS 17/2.8 cells which was statis- 
tically significant with doses as low as 0.5 ng/ml TGF- 
& (48 h pre-treatment) (Fig. 5). The treatments were 
routinely placed in cell culture media containing low 
levels of fetal bovine serum since higher serum levels 
stimulated PTH/PTHrP receptor levels and masked 
the TGF-/I, effects (data not shown). Evaluation of 
PTHrP competitive binding (Fig. 6) by Scatchard analy- 
sis indicated that the binding affinity of PTHrP was 
similar for TGF-&-treated (5.0 ng/ml) and control 
cells (Table 1) and similar to that reported by other 
investigators for osteoblastic cells (Nissenson et al., 
1988; Abou-Samra et al., 1989). Calculation of the 
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Fig. 7. Time course of [1251]PTHrP binding to ROS 17/2.8 cells 
pretreated with TGF-Pi (5.0 ng/ml in media containing 1% FBS). 
Specific binding is the total cpm bound with no added unlabeled 
PTHrP minus the cpm bound in the presence of an excess of 
unlabeled PTHrP (1 FM) and is expressed as a percent of the total 
cpm (25000) applied per well. There was a significant increase in % 
specific binding in TGF-&-treated cells at 24, 48 and 72 h. Data 
expressed as mean + SEM of triplicate wells. 
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Fig. g. Effects of 48 h pre-incubation with TGF-p, (0, 0.15, 0.25 
ng/ml in media containing 1% FBS) on PTH-stimulated (10 min 
exposure) CAMP levels in ROS 17/2.8 cells. Levels of CAMP per lo3 
cells in triplicate samples are shown (mean* SEM). There was no 
significant difference in control levels of CAMP (no PTH-stimula- 
tion) with TGF-/?, pre-incubation; however, with PTH-stimulation, 
CAMP levels were greater (p < 0.05) with 0.5 ng/ml and 1.0 ng/ml 
vs. 0 ng/ml TGF-j3,. 
increase of approximately 55% in numbers of receptors 
when the ROS cells were pre-incubated with TGF-P, 
for 48 h. The cell number as determined by trypan blue 
dye exclusion in treatment and control groups was not 
different (data not shown). There was a significant 
increase in percent specific binding after 24 h of TGF- 
P-treatment (5.0 ng/ml) which increased up to 48 h; 
and remained increased at 72 h (Fig. 7). 
3.3. Adenyla te cyclase stimulation assay 
The ability of TGF-Pi to alter PTH-stimulated 
adenylate cyclase activity was evaluated in confluent 
ROS cells pre-incubated with TGF-P, (0, 0.1, 0.5, 1.0 
ng/ml) followed by a 10 min PTH stimulation (10 nM). 
There was no difference in the basal levels of CAMP in 
cells pre-incubated with TGF-P,; however, significantly 
greater levels of CAMP were found in response to 
PTH-stimulation in the 0.5 and 1.0 ng/ml TGF-Pi-pre- 
treated cells (Fig. 8). 
4. Discussion 
The present study provides the first evidence for 
upregulation of the PTH/PTHrP receptor by TGF-Pi 
at the level of mRNA expression in osteoblastic cells. 
Previous reports have indicated that TGF-P enhanced 
PTH stimulation of adenylate cyclase in osteoblastic 
cells (ROS 17/2.8 and UMR-106) and TGF-& inhib- 
ited adenylate cyclase and PTHrP binding in renal 
(OK) cells (Gutierrez et al., 1990; Schneider et al., 
1992; Seitz et al., 1992; Law et al., 1993). Gutierrez et 
al. (1990) suggested that TGF-/3 did not alter PTH 
receptor affinity which is in agreement with our find- 
ings; however they also suggested that the modulatory 
effect of TGF-P was localized to nonreceptor compo- 
nents of the adenylate cyclase system. We found that 
PTH-stimulated CAMP levels, PTHrP receptor binding 
and PTH/PTHrP receptor mRNA upregulation were 
significantly elevated with similar levels of TGF-P, in 
ROS cells. This indicates that TGF-Pi acts directly to 
increase PTH/PTHrP receptor numbers on osteoblas- 
tic cells by increasing the steady state PTH/PTHrP 
receptor mRNA levels. This is in support of findings by 
Schneider et al. (1992) which found an increase in 
PTH/PTHrP receptors and the G protein stimulatory 
subunit with TGF-P-treatment of UMR-106 osteoblas- 
tic cells. 
TGF-/3 upregulates the binding of PTH on chondro- 
cytes and osteoblastic cells, both of which require 24-48 
h of incubation with TGF-/3 (Takigawa et al., 1991; 
Schneider et al., 1992). This is in agreement with our 
studies since specific binding increased over a 48 h 
period. Our study indicates that mRNA levels are 
increased in response to TGF-Pi as early as 6 h, which 
is indicative of a rapid effect of TGF-/3, on ROS cells; 
the resultant increase in the receptor determined by 
ligand binding reached a peak at 48 h. 
The results of this study indicate that the upregula- 
tion of the PTH/PTHrP receptor mRNA is rapid; 
however, it is dependent on the synthesis of another 
protein(s) since cycloheximide inhibited the TGP-Pi-in- 
duced upregulation of PTH/PTHrP receptor mRNA. 
Alternately, the cycloheximide may have effected an 
increase in the transcription of a gene whose product 
inhibited PTH/PTHrP receptor gene transcription. 
TGF-P has been reported to have a wide variety of 
effects on osteoblastic cells dependent on the state of 
differentiation of the cell. Clonal populations of rat 
osteoblastic cells exposed to TGF-P, respond differ- 
ently to PTH stimulation based on the differentiation 
state. Mature osteoblastic cells have increased PTH- 
stimulated CAMP levels in response to TGF-&; 
whereas osteoblast precursors do not have altered PTH 
responses with TGF-/?, treatment (Yamaguchi et al., 
1991). Furthermore, preliminary data indicate that pri- 
mary rat calvarial cells respond to TGF-& with a 
decrease in PTH responsiveness (Jongen et al., 1993). 
Inconsistencies in TGF-P actions on osteoblasts in 
vitro suggest that the stage of differentiation, dose, and 
culture conditions may alter TGF-P effects. The results 
from our study are consistent with the ROS 17/2.8 
cells representing a mature osteoblastic cell type that 
responds to TGF-/?, with increased numbers of 
PTH/PTHrP receptors. Other phenotypic characteris- 
tics of a differentiated osteoblastic cell that have been 
reported to be stimulated by TGF+, in ROS 17/2.8 
cells include alkaline phosphatase activity, osteopontin, 
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and type I collagen (Centrella et al., 1988; Pfeilschifter 
et al., 1990; Noda and Rodan, 1987). Since TGF-& is 
present in large amounts in the extracellular matrix of 
bone, and is released and activated during bone re- 
sorption, it has been thought to be an important factor 
in the process of coupling of bone resorption and bone 
formation (Pfeilschifter et al., 1990). The results from 
this study indicate that TGF-/3, may exert its effects on 
the bone remodeling cycle at least in part by its ability 
to regulate PTH/PTHrP receptor mRNA, its transla- 
tion product, and signaling pathway. 
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